Platelet-derived growth factor receptor α (PDGFRα) exhibits divergent effects in skeletal muscle. At physiological levels, signalling through this receptor promotes muscle development in growing embryos and angiogenesis in regenerating adult muscle 1,2 . However, both increased PDGF ligand abundance and enhanced PDGFRα pathway activity cause pathological fibrosis 3,4 . This excessive collagen deposition, which is seen in aged and diseased muscle 5-7 , interferes with muscle function and limits the effectiveness of gene-and cell-based therapies for muscle disorders 8,9 . Although compelling evidence exists for the role of PDGFRα in fibrosis, little is known about the cells through which this pathway acts. Here we show in mice that PDGFRα signalling regulates a population of muscle-resident fibro/adipogenic progenitors (FAPs) that play a supportive role in muscle regeneration but may also cause fibrosis when aberrantly regulated 10-13 . We found that FAPs produce multiple transcriptional variants of Pdgfra with different polyadenylation sites, including an intronic variant that codes for a protein isoform containing a truncated kinase domain. This variant, upregulated during regeneration, acts as a decoy to inhibit PDGF signalling and to prevent FAP over-activation. Moreover, increasing the expression of this isoform limits fibrosis in vivo in mice, suggesting both biological relevance and therapeutic potential of modulating polyadenylation patterns in stem-cell populations.
We found that FAPs produce not only transcriptional variants of Pdgfra that harbour different polyadenylation sites within the 3′ UTR, but also multiple transcripts that are polyadenylated at introns within the protein-coding region (Fig. 1a ). We confirmed polyadenylation at these sites through 3′ rapid amplification of cDNA ends (RACE) ( Fig. 1b and Extended Data Fig. 2a ). Particularly noteworthy was a transcriptional variant (which we term 'In-PDGFRα ') that terminates within intron 16 of Pdgfra. This transcript, the most abundant of the intronic variants, contains the canonical AAUAAA polyadenylation termination motif preceded by an in-frame stop codon sequence, suggesting protein-coding potential. Such a protein would consist of a membrane-bound isoform of PDGFRα containing an intact ligand-binding domain but a truncated kinase domain (Extended Data Fig. 2b, c) . This type of structural modification is notable because previous studies in cell lines have suggested that protein truncations produced through intronic polyadenylation can substantially affect functionality of the full-length counterpart 20 . For example, artificial induction of intronic polyadenylation of tyrosine kinase receptors, in which both the kinase and transmembrane regions were truncated, caused cells to produce soluble decoy receptors that bound ligand or functional receptors, suppressing signalling 21 .
Given that the kinase domain of In-PDGFRα is disrupted, we proposed that this protein could act as a decoy to negatively regulate PDGF signalling. We therefore investigated whether the In-PDGFRα transcript produced a functional protein in FAPs. Indeed, whereas western blot analysis of FAP lysates using a C-terminal-directed antibody revealed a band at 180 kDa corresponding to the full-length protein (FL-PDGFRα ) ( Fig. 1c) , an antibody directed at a central region of PDGFRα detected bands at both 180 kDa and 120 kDa ( Fig. 1d ). Overexpression of In-PDGFRα in FAPs using a retroviral construct resulted in increased levels of a 120-kDa protein (Fig. 1e ).
Use of the identified stop codon in intron 16 would be expected to result in an extension of the stretch of 16 amino acids unique to In-PDGFRα (Extended Data Fig. 2d ). We developed a polyclonal antibody directed against this specific 16-amino-acid peptide. This antibody detected a band at 120 kDa but not at 180 kDa in untreated FAPs. The 120 kDa band was also detected in cells overexpressing In-PDGFRα , demonstrating that it specific for In-PDGFRα (Fig. 1e) .
To investigate the specific regulation of In-PDGFRα production, we analysed FAPs activated in response to muscle injury. Overall levels of FL-PDGFRα increased but there was also a marked increase in the proportion of In-PDGFRα to FL-PDGFRα , peaking 3-5 days after injury ( Fig. 1f ), suggesting differential regulation of the intronic variant relative to the full-length form. After 3 weeks, the relative levels of In-PDGFRα were comparable to those in uninjured muscle (Fig. 1f ). Using primers that could specifically detect In-PDGFRα and FL-PDGFRα (Extended Data Fig. 2d, e ), we found a similar temporal pattern at the transcriptional level (Extended Data Fig. 2f ).
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To evaluate the effect of intronic polyadenylation on PDGFRα activity, we used antisense morpholino oligonucleotides (AMOs), which can alter intronic polyadenylation site usage by blocking splicing and polyadenylation machinery 21 . We designed AMOs to target the intronic polyadenylation site (pA-AMOs) and the upstream 5′ splice site (5′ ss-AMO) expected to decrease and increase production of In-PDGFRα , respectively ( Fig. 2a ). We measured the effect of these morpholinos on both In-PDGFRα transcript and protein levels. The pA-AMOs decreased levels of In-PDGFRα without altering FL-PDGFRα expression (Fig. 2b, c and Extended Data Fig. 2g ). Similarly, the 5′ ss-AMO increased In-PDGFRα levels, and there was a corresponding reduction of FL-PDGFRα expression ( Fig. 2d , e and Extended Data Fig. 2g ).
We then investigated whether modulation of the levels of the intronic variant could alter PDGFRα signalling. Treatment of cells with PDGF-AA led to phosphorylation of PDGFRα and downstream components including ERK1/2 and Akt (Extended Data Fig. 3a, b ). If In-PDGFRα serves as a decoy, we would expect decreased PDGFRα signalling when this variant is upregulated. As expected, pre-treatment of cells with the 5′ ss-AMO, which increases In-PDGFRα abundance, led to reduced ERK1/2 and Akt phosphorylation ( Fig. 2f, g) , an effect also observed when we overexpressed In-PDGFRα (Extended Data Fig. 3c ). Conversely, pre-treatment of cells with the pA-AMOs resulted in increased ERK1/2 phosphorylation ( Fig. 2h , i).
These changes in signalling were also accompanied by changes in FAP activation. FAPs treated with the pA-AMOs exhibited an increased proliferative response to PDGF-AA ( Fig. 3a and Extended Data Fig. 4a -c), as did cells treated with an In-PDGFRα -specific short interfering RNA (siRNA) (Extended Data Figs 4d, 5a-d). By contrast, upregulation of In-PDGFRα by 5′ ss-AMO pre-treatment blunted PDGF-induced proliferation ( Fig. 3b and Extended Data Fig. 4e ), as did the overexpression of In-PDGFRα (Extended Data Fig. 4f ). In independent functional assays, we found that pre-treatment 
with pA-AMOs increased FAP proliferation and migration whereas 5′ ss-AMO pre-treatment resulted in a decrease ( Fig. 3c ).
We also investigated the effects of In-PDGFRα modulation on FAP differentiation. FAPs treated with PDGF-AA showed upregulation of key fibrosis markers and induction of downstream TGFβ signalling (Extended Data Fig. 6a , b), consistent with previous studies 12 . Notably, gene expression of FAPs treated with pA-AMOs, in which In-PDGFRα levels are decreased, revealed a pattern consistent with enhanced activation and fibrotic differentiation. In particular, there was enrichment for DNA replication and cell cycle genes including the MAPK-ERK pathway (Extended Data Fig. 6c -e). Moreover, causal network analysis suggested that TGFβ 1 signalling was active in these cells ( Fig. 3d ) with increased expression of associated fibrosis mediators including connective tissue growth factor. Conversely, the inhibition of PDGFRα signalling through 5′ ss-AMO-mediated In-PDGFRα upregulation did not significantly change gene expression associated with TGFβ 1 activation. Instead, there was enrichment for processes related to protein and/or RNA processing and metabolism (Extended Data Fig. 6f -h). The top predicted regulators included Pparg (Fig. 3e ); the activity of this gene is associated with a reduction in fibrosis and TGFβ signalling in several tissues 22 .
Given these findings and the association of FAPs with fibrosis, we hypothesized that altering PDGF signalling in FAPs by modulating In-PDGFRα levels in vivo would affect muscle fibrosis following injury. Therefore, we designed PDGFRα -specific vivo-morpholinos (VMOs), a class of morpholinos that can enter cells directly because of a covalently bound delivery moiety 23 . The VMOs targeting the polyadenylation site (pA-VMOs) and the 5′ -splice-site (5′ ss-VMO) were designed to contain the same targeting sequences as their AMO counterparts. We tested these VMOs both in vitro and in vivo and observed that their effects on In-PDGFRα and FL-PDGFRα levels mimicked those of their corresponding AMOs (Fig. 4a, b and Extended Data Fig. 7a, b ). Using intramuscular injection of VMOs in mice, we found that the 5′ ss-VMO resulted in a decreased FAP proliferation index and a corresponding decrease in FAP numbers (Extended Data Fig. 7c, d) . Treatment with pA-VMOs did not enhance FAP proliferation significantly, possibly because cells are already maximally stimulated by the injury response in vivo (Extended Data Fig. 7c, d) .
In parallel to our in vitro analyses, FAPs isolated from muscle pre-treated with pA-VMOs displayed increased proliferation and enhanced migration ( Fig. 4c, d) . Moreover, expression analysis of these LETTER RESEARCH cells revealed enrichment for terms related to proliferation including cell cycle and mitosis (Extended Data Fig. 7e ). Notably, causal network analysis was significant (P < 0.05) for several proliferation and fibrosis regulators including connective tissue growth factor, a growth factor that is upregulated by TGFβ and has been shown to increase collagen production by fibroblasts and to promote tissue fibrosis 8 (Extended Data Fig. 7g ). By contrast, 5′ ss-VMO-treated FAPs showed decreased proliferation and migration ( Fig. 4c, d) as well as enrichment for interferon signalling (Extended Data Fig. 7f, h) , which has been shown to decrease fibroblast activation and reduce fibrosis levels in models of hepatic and renal injury 24 .
We hypothesized that enhancing FAP activity through inhibition of In-PDGFRα via intramuscular injection of pA-VMOs would enhance fibrosis following injury. Indeed, this occurred in two separate models of muscle injury ( Fig. 4e and Extended Data Fig. 8 ). Although FAPs have been implicated as key mediators of fibrosis, the ability of pA-VMOs to promote fibrosis, albeit with a more modest effect on FAP proliferation in vivo (Extended Data Fig. 7c, d) , could reflect the contribution of other cell types to the fibrotic response. We next investigated whether the 5′ ss-VMO, because of its potential to block PDGFRα signalling, could decrease fibrosis. Notably, not only did injection of the 5′ ss-VMO decrease fibrosis following injury in young adult muscle ( Fig. 4f and Extended Data Fig. 8 ), but also overall levels of fibrosis were significantly reduced (P < 0.01) in aged muscle ( Fig. 4g ), where this type of pathology is more pronounced 5 .
Our finding that Pdg fra is subject to intronic polyadenylation and that this process influences FAP activation suggests that polyadenylation site choice can serve as a mechanism by which stem cells adjust levels of molecular signalling. VMOs are attractive candidates for disease treatment because of their sequence specificity, stability, resistance to degradation and lack of interaction with cellular structures 25 . Their utility in reducing tissue fibrosis through experimental manipulation of Pdgfra intronic variant levels suggests that modulating polyadenylation site selection could be a promising therapeutic approach to the treatment of fibrotic diseases and disorders.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.

METHODS
Animals.
Wild-type male C57BL/6 mice and B6.129S4-PDGFRα tm11(EGFP)Sor /J mice (Jackson strain number 007669), which contain an H2B-eGFP fusion protein knocked into the Pdgfra locus, were obtained from Jackson Laboratories. Young adult mice were 6-8 weeks of age; aged mice were 22-24 months of age. Mice were housed and maintained in the Veterinary Medical Unit at the Veterans Affairs Palo Alto Health Care System. Animal protocols were performed in accordance with the policies of the Administrative Panel on Laboratory Animal Care of Stanford University. Muscle injury. Mice were anaesthetized using isoflurane. To assess muscle regeneration, 50 μ l of a 1.2% barium chloride (BaCl 2 ) solution (Sigma-Aldrich) was injected into tibialis anterior muscles as described previously 5 . To isolate activated FAPs for western blot analysis and FACS analysis, 50 μ l of 1.2% BaCl 2 or 50% (v/v) glycerol/water was injected throughout the lower hindlimb muscles. For induction of fibrosis, 30 μ l of 50% (v/v) glycerol or 30 μ l 1.2% BaCl 2 solution was injected into tibialis anterior muscles. Isolation of FAPs. Muscles were dissected from mice and dissociated mechanically. All hindlimb muscles were used except in experiments where FAPs were isolated from VMOs injected into tibialis anterior muscles. In this case, only the tibialis anterior muscle was dissected. The muscle suspension was digested using collagenase II (760 U ml −1 ; Worthington Biochemical Corporation) in Ham's F10 medium (Invitrogen) with 10% horse serum (Invitrogen) for 90 min at 37 °C with agitation. The suspension was then washed and digested in collagenase II (152 U ml −1 ; Worthington Biochemical Corporation) and dispase (2 U ml −1 ; Invitrogen) for 30 min at 37 °C with agitation. The resultant mononuclear cells were then stained with the following antibodies: VCAM-1-biotin (clone 429; BioLegend, 105704), CD31-APC (clone MEC 13.3; BioLegend, 102510), CD45-APC (clone 30-F11; BioLegend, 103112) and Sca-1-Pacific Blue (clone D7; BioLegend, 108120) at 1:75. Streptavidin-PE-Cy7 (BioLegend, 405206) at 1:75 was used to amplify the VCAM-1 signal. FAPs were collected according to the following sorting criteria: CD31 − CD45 − Sca-1 + . FACS was performed using BD-FACS Aria II and BD-FACS Aria III cell sorters equipped with 488 nm, 633 nm and 405 nm lasers. The cell sorters were carefully optimized for purity and viability and sorted cells were subjected to FACS analysis immediately after sorting to confirm FAP purity. Direct RNA sequencing. FAPs were isolated from uninjured C57BL/6 mice as described above and lysed. RNA was prepared with the RNeasy Mini Kit as per the manufacturer's instructions (Qiagen). A 3′ blocking reaction was performed using a poly(A) tailing kit (Ambion) and 3′ -dATP (Jena Bioscience) and the reaction mixture was incubated at 37 °C for 30 min. RNA was hybridized to flow cell surfaces for direct RNA sequencing as previously described 18 . Raw direct RNA sequencing reads were filtered using the Helicos-developed pipeline, Helisphere, to eliminate reads less than 25 nucleotides long or of low quality. These reads were then mapped to the mouse genome (NCBI37/mm9) using an IndexDPgenomic module and reads with a score above 4.3 were allowed. To avoid artefacts from mispriming, reads mapping to regions in the genome where more than four consecutive adenines were coded immediately 3′ to the mapping sequence were excluded from further analysis. Reads were viewed using the Integrative Genomics Viewer 32, 33 . Analysis of alternative polyadenylation sites and quantitative RT-PCR. Total RNA was extracted from FAPs isolated from uninjured C57BL/6 mice using TRIzol (Invitrogen) as per the manufacturer's instructions. To identify the polyadenylation sites, the sample was reverse transcribed using the SMARTer RACE cDNA amplification kit (Clontech) according to the manufacturer's instructions using the primers listed in Extended Data Table 1 . The amplified fragments were subcloned into pGEM-T-Easy (Promega) and sequenced. Sequencing data were visualized with 4Peaks. To assess levels of the intronic variant and UTR variants, primers were designed to span the Pdgfra transcript (Extended Data Table 2 ). Variant expression was normalized to Gapdh using the comparative C t method 27 and reported relative to the average of control-treated samples. Retroviral transfection. A construct corresponding to In-PDGFRα (DNAFORM, AK035501, RIKEN clone 9530057A20) was obtained. This construct was subcloned into the pMXs-IRES-GFP retroviral backbone (Cell BioLabs, Inc.) to generate pMXs-I-Pα . Replication-incompetent retroviral particles were generated by transfection of the 293T human embryonic kidney cell-derived Phoenix helper cell line (gift from G. Nolan). Viral supernatant was filtered through 0.45-μ m polyethersulfone filters, concentrated using PEG precipitation and stored at − 80 °C.
FAPs were plated in 6-well plates and grown in DMEM supplemented with 10% fetal bovine serum (FBS). When cells reached 70% confluency, viral supernatant and polybrene (at a final concentration of 4 μ g ml −1 ) were added to the medium. For overexpression experiments, FAPs were incubated with the viral supernatant for 48 h before analysis. For signalling assays, FAPs were incubated with the viral supernatant for 24 h. Afterwards the medium was changed to serum-free DMEM containing viral supernatant and the cells were incubated for an additional 24 h. The FAPs were then treated with 1 ng ml −1 PDGF-AA for 15 min, after which the cells were used for western blot analysis.
Generation of an In-PDGFRα-specific rabbit polyclonal antibody. A peptide with the sequence GKSAHAHSGKYDLSVV, which represents the unique C-terminal region of In-PDGFRα protein, was generated (Thermo Scientific Pierce, OE0726). To generate In-PDGFRα rabbit polyclonal antibodies directed against In-PDGFRα , New Zealand white rabbits that were specific pathogen free were immunized with 0.25 mg of the peptide in Complete Freund's Adjuvant. The rabbits received three boosters of antigen consisting of 0.10 mg in Incomplete Freund's Adjuvant at days 14, 42 and 56 after immunization. Serum was collected at days 70 and 72 (Thermo Scientific Pierce). Western blot analysis. Cells and homogenized tissues were lysed with RIPA lysis buffer supplemented with protease and phosphatase inhibitors (Roche). The lysates were run on Criterion SDS-PAGE gels (Bio-Rad), transferred to nitrocellulose membranes (Fisher Scientific), and analysed by western blot using the following rabbit antibodies: PDGFRα polyclonal (1:1,000, Cell Signaling, 3174), PDGFRα centre (1:100, Abgent, AP14254c), In-PDGFRα custom (1:1,000) , pPDGFRα Tyr754 polyclonal (1:1,000, Cell Signaling, 4547), Akt polyclonal (1:1,000, Cell Signaling, 9272), pAkt polyclonal (1:1,000, Cell Signaling, 9271), PLCγ polyclonal (1:1,000, Cell Signaling, 5690), pPLCγ polyclonal (1:1,000, Cell Signaling, 2821), ERK polyclonal (1:2,000, Cell Signaling, 4695), pERK polyclonal (1:2,000, Cell Signaling, 4370), SMAD2/3 monoclonal (1:1,000, Cell Signaling, 8685), and pSMAD2 Ser465/Ser467 / SMAD3 Ser423/Ser425 monoclonal (1:1,000, Cell Signaling, 8828). Membranes were incubated in horseradish-peroxidase-labelled secondary antibodies and bands were visualized with enhanced chemiluminescence (Advansta). siRNA knockdown of PDGFRα variants. siRNAs were designed using the Dharmacon siDESIGN Center for knockdown of In-PDGFRα and FL-PDGFRα (Extended Data Table 2 ). To knockdown either In-PDGFRα or FL-PDGFRα in FAPs, approximately 8 × 10 4 cells were plated in a 12-well plate containing DMEM supplemented with 10% FBS and grown to 70-80% confluence. Cells were incubated in 200 nM of either PDGFRα or control siRNAs using Lipofectamine 2000 (Invitrogen). To assess knockdown, cells were collected at 24 h for qPCR analysis. For western blot analyses, 3 × 10 5 cells were plated in 6-well plates and incubated in Ham's F10 medium (Invitrogen) supplemented with 10% horse serum (Invitrogen) for 24 h. The medium was then replaced with serum-free Ham's F10 (Invitrogen) supplemented with 200 nM siRNA and incubated for an additional 24 h. Antisense morpholino treatment. Morpholinos were designed to target two polyadenylation sites on the intronic variant (pA 1 : 5′ -TGATTACAT TATATCTGTCTTTATT-3′ and pA 2 : 5′ -AGCAAAGACCATCATAGCAGA ATGA-3′ ) and the upstream 5′ splice site of the intron (5′ ss: 5′ -ATGGGCACTT TTACCTAGCATGGAT-3′ ) (Gene Tools, LLC). For in vitro treatment, cells were grown to 70-80% confluency in DMEM (Invitrogen) supplemented with 10% FBS (Atlanta Biologicals). Cells were incubated in 10 μ M of the indicated morpholino using the Endo-Porter transfection reagent (Gene Tools, LLC). Cells were collected at 24 h for qPCR analysis with RNA isolated using the RNeasy Plus Mini kit with on-column DNase digestion as per manufacturer's instructions (Qiagen). For western blot analysis, cells were transfected for 24 h in Ham's F10 medium (Invitrogen) supplemented with 10% horse serum (Invitrogen). The medium was then replaced with serum-free Ham's F10 (Invitrogen) and incubated for an additional 24 h. For signalling assays, cells were then incubated for 15 min with PDGF-AA (Peprotech) at 0.1 ng ml −1 or 20 ng ml −1 for cells treated with pA-AMOs or 5′ ss-AMO, respectively, and lysed for western blot analysis as described above. In vitro EdU incorporation assay. For AMO treatment, FAPs were isolated from the uninjured hindlimb muscles of C57BL/6 mice and seeded at 1 × 10 5 cells per well in poly-d-lysine-coated 8-well chamber slides (BD Biosciences) coated with ECM gel (Sigma-Aldrich). Cells were transfected with 10 μ M AMO using Endoporter (Gene Tools) and expanded for 2 days in Ham's F10 (Invitrogen) supplemented with 10% horse serum (Invitrogen). The medium was then replaced with Opti-MEM supplemented with 2 ng ml −1 PDGF-AA ligand and 10 μ m EdU (Invitrogen). Cells were fixed in 4% paraformaldehyde (Sigma-Aldrich) after 24 h.
For siRNA treatment, FAPs were isolated from the uninjured hindlimb muscles of C57BL/6 mice and seeded at 2 × 10 5 cells per well in poly-d-lysine coated 8-well chamber slides (BD Biosciences) coated with ECM gel (Sigma-Aldrich). The medium was supplemented with 200 nM siRNA and transfected using Lipofectamine 2000 (Invitrogen). After 24 h, the medium was replaced with Opti-Mem and the cells were re-transfected with 200 nM siRNA and 50 ng ml −1 PDGF-AA. In siRNA-treated samples, EdU was not included in this medium. Rather, after 20 h the medium was replaced with Opti-Mem containing 10 μ m EdU (Invitrogen). Cells were fixed 4 h later.
For retroviral overexpression of In-PDGFRα , FAPs were isolated from uninjured hindlimbs of C57BL/6 mice and seeded at 2 × 10 5 cells per well in poly-d-lysine coated 8-well chamber slides (BD Biosciences) coated with ECM gel (Sigma-Aldrich). FAPs were cultured in DMEM supplemented with 10% FBS along with viral supernatant and 4 μ g ml −1 polybrene. After 24 h, the medium was LETTER RESEARCH replaced with serum-free DMEM containing viral supernatant and 20 ng ml −1 PDGF-AA. Twenty hours later, the medium was replaced with Opti-MEM containing 10 μ M EdU. Cells were fixed after 4 h. For EdU incorporation experiments, cells were stained using the Click-iT EdU Imaging Kit (Invitrogen). Cells were analysed on a Zeiss Observer Z1 fluorescent microscope (Carl Zeiss) equipped with a Hamamatsu Orca-ER camera (Hamamatsu) and Improvision Volocity software (Perkin Elmer). Scratch assay. Cells isolated by FACS from uninjured hindlimb muscles were seeded at a density of 3.5 × 10 4 cells per well in 96-well plates in Ham's F10 medium supplemented with 2% horse serum. After 48 h, cells were nearly confluent and the medium was changed to Ham's F10 with 2% horse serum and 20 ng ml −1 PDGF-AA. A wound was made by scratching a 200-μ l pipette tip across the monolayer of cells. The initial scratch area was determined immediately and set to 100%. Images were taken at regular intervals and the scratch area at each time point was measured and calculated as a percentage of the initial scratch area. Scratch closure is defined as the inverse of the cell-free area as a percentage of total area. Microarray analysis. For in vitro microarray analysis, FAPs were isolated from the uninjured hindlimb muscles of C57BL/6 mice. Cells were plated at 1 × 10 6 cells per well in 12-well plates. Cells were grown for 2.5 days in DMEM supplemented with 10% FBS. The medium was switched to Ham's F10 supplemented with 10% horse serum and transfected with 10 μ M AMO as indicated for 48 h. The medium was then replaced with Opti-Mem and cells were re-transfected with 10 μ M AMO. After 48 h, the cells were lysed and RNA was prepared with the RNeasy Mini Kit as per the manufacturer's instructions (Qiagen). For in vivo microarray analysis, tibialis anterior muscles were injured with 30 μ l of glycerol each and injected with the indicated VMO after 3 days. FAPs were then isolated from the muscles 2 days after VMO injection. Cells were pelleted and RNA prepared from samples as indicated above. The microarray data were obtained using Affymetrix Mouse 1.0 ST. For gene set enrichment analysis (GSEA), the samples were normalized and processed using GenePattern ExpressionFileCreator and PreProcessData set modules. Expression data were analysed and visualized with GSEA 28 and GENE-E (http://www.broadinstitute.org/cancer/software/GENE-E/). For ingenuity pathway analysis, including causal network analysis, the samples were normalized using Affymetrix Expression Console Software and analysed for enrichment using IPA (Ingenuity Systems, http://www.ingenuity.com). Array data were deposited into Gene Expression Omnibus (Accessions GSE60099 and GSE81744). Vivo-morpholino treatment. Vivo-morpholinos were designed to target two polyadenylation sites on the intronic variant (pA 1 -VMO: 5′ -TGATTACATTAT ATCTGTCTTTATT-3′ and pA 2 -VMO: 5′ -AGCAAAGACCATCATAGC AGAATGA-3′ ) and the upstream 5′ splice site of the intron (5′ ss-VMO: 5′ -ATG GGCACTTTTACCTAGCATGGAT-3′ ) (Gene Tools, LLC). For treatment in vitro, cells were isolated from hindlimb muscles of C57BL/6 mice and grown to 70-80% confluency in DMEM (Invitrogen) supplemented with 10% FBS (Atlanta Biologicals). Cells were incubated in the 10 μ M of the indicated morpholino (Gene Tools, LLC). Cells were collected at 24 h for qPCR analysis. For in vivo qPCR analysis, tibialis anterior muscles were injured with glycerol as described above and injected with 250 ng of the indicated VMO at the site of injury 3 days later. FAPs were sorted by FACS 7 days after VMO injection for qPCR analysis.
For ex vivo proliferation and scratch assays, tibialis anterior muscles were injured with glycerol and injected with 250 ng of the indicated VMO 3 days after injury. FAPs were isolated 2 days later by FACS. In EdU incorporation studies, cells were seeded at 4 × 10 4 cells per well in poly-d-lysine-coated 8-well chamber slides (BD Biosciences) coated with ECM gel (Sigma-Aldrich). Cells were incubated in 10 ng ml −1 PDGF-AA (Peprotech) and 10 μ M EdU (Invitrogen) for 24 h. The cells were fixed and stained. In the ex vivo proliferation studies as well as the in vivo proliferation studies described below, the proliferation index was used to denote the percentage EdU incorporation normalized to control. In the scratch assays, cells were seeded and treated as described above.
For in vivo proliferation studies, tibialis anterior muscles were injected with 150 ng of the indicated VMO at 0 and 24 h. FAPs were isolated at 48 h via FACS. To assess in vivo proliferation, the cells were exposed to 10 μ M EdU immediately after muscle isolation and incubated in 10 μ M EdU ex vivo during the collagenase, collagenase/dispase, and antibody incubations as described above. The cells were plated in poly-d-lysine-coated 8-well chamber slides (BD Biosciences) coated with ECM gel (Sigma-Aldrich), fixed 1 h after plating, and stained using the Click-iT EdU Imaging Kit (Invitrogen).
For histological analysis, tibialis anterior muscles were injured with glycerol or BaCl 2 and injected at the site of injury with 250 ng of the indicated VMO. After 7 days, the muscles were snap frozen in isopentane cooled in liquid nitrogen immediately after dissection. Muscles sections were stained with Gomori-trichrome (Richard-Allan Scientific) per manufacturer's instructions or oil red O (Sigma-Aldrich) as previously described 29 . The fibrotic index was calculated as the area of fibrosis divided by total area of muscle normalized to control-treated muscle. The fibro-adipose index was defined as the area of fibrosis plus the area of adiposis (as detected by oil red O staining) divided by total area of muscle, normalized to control. Statistics and general methods. Major factors in determining sample size included the level of the effect and the inherent variability in measurements obtained. No statistical methods were used to predetermine sample size. Animals were excluded from the study only if their health status was compromised, such as occurred when animals had visible wounds from fighting. Samples were not specifically randomized or blinded. However, mouse identifiers were used when possible to blind evaluators to experimental conditions, and all samples within experiments were processed identically for measurement quantification using automated tools as specified. Data availability. The sequencing data were deposited into the NCBI Sequence Read Archive (accession number SRP079186). Array data were deposited into Gene Expression Omnibus (accession numbers GSE60099 and GSE81744).
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Extended Data Figure 1 | PDGFRα is activated specifically in FAPs during muscle regeneration. a, Tibialis anterior muscles were dissected on the indicated days after injury. The muscle lysates were subjected to western blot to probe for PDGFRα and pPDGFRα using different antibodies, which shows increased expression of pPDGFRα during muscle regeneration. b, Quantification of a (n = 3 individual tibialis anterior muscles per time point). pPDGFRα level refers to expression levels for pPDGFRα normalized to total PDGFRα . Error bars represent s.e.m. c, Immunofluorescence of an uninjured tibialis anterior muscle and a muscle 4.5 days after injury shows an increase in the abundance of pPDGFRα -expressing cells during the regenerative process. (DAPI, blue; laminin, red; pPDGFRα , green). d, Immunofluorescence of an uninjured tibialis anterior muscle from a PDGFRα -eGFP reporter mouse. e, FACS histogram analysis of the GFP signal in a PDGFRα -eGFP reporter heterozygote (green line) and in a wild-type littermate (grey, solid) in cells from uninjured hindlimb muscles. f, FACS plot of cells isolated from uninjured hindlimb muscles of the PDGFRα -eGFP reporter. GFPpositive cells (shown in green) are overlaid upon all cells (shown in grey). Dashed lines represent the gate for the FAP population. g, Histograms showing GFP signal in cell populations isolated from uninjured PDGFRα -eGFP reporter mice, as detected by FACS analysis. h-j, The patterns of expression of h, i, and j, as assessed by FACS analysis of BaCl 2 -injured muscle were similar to the patterns in e, f, and g, respectively, from uninjured muscle. k-m, Similarly, the patterns of expression of k, l, and m, as evaluated by FACS analysis of glycerol-injured muscle were comparable to the patterns in e, f, and g, respectively, from uninjured muscle. Treatment with pA-VMOs does not lead to a significant change in proliferation (P = 0.42). e, f, GSEA of FAPs collected from tibialis anterior muscles treated with pA-VMOs (e) or the 5′ ss-VMO (f), compared to control-treated samples, were analysed for enrichment of pathways in the Reactome database 30, 31 . Top sets with a false discovery rate of less than 5% are shown. g, h, Ingenuity pathway analysis of top regulators of gene expression in FAPs treated with pA-AMOs (g) or the 5′ ss-VMO (h) compared to control treatment. The top hits are shown, excluding those with the 'molecular type' designated as a chemical or drug. For a-d, n represents biological replicates of pooled FAPs. * P < 0.05; * * P < 0.01, * ** P < 0.001, * ** * P < 0.0001; unpaired Student t-tests. In g, h, two pooled FAP samples per condition were used with the overlap P-value calculated using the Fisher's exact test. Error bars represent s.e.m. TBX2  ESR1  PTGER2  RABL6  E2F  FOXM1  MED1  EP400  VEGF  AR  IRF5  MAVS  IL27  CSF2  FOXO1 AKT E2F1 MKL2 EHF CTGF Activation Z-Score Activation Z-Score IFNG  IRF7  IFNAR  Interferon Alpha  IRF3  IFNB1  IFNA2  STAT1  PRL  IFNL1  TICAM1  MYD88  NFkB (complex)  TLR9  TLR3  MAVS  IFN  IFN Beta  TLR4 
